Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
| Autor: | Adam Hołub, Piotr Jerzmanowski, Urszula Tęgowska, Anna Rychter, Ilona Seferynska, Violetta Kalinowska, Joanna Góra-Tybor, Zofia Specht-Szwoch, Ewa Lech-Marańda, Agnieszka Kołkowska-Leśniak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty medicine.drug_class Dasatinib Tyrosine kinase inhibitor Antineoplastic Agents Tyrosine-kinase inhibitor Medication Adherence Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive Surveys and Questionnaires medicine Humans Protein Kinase Inhibitors Chronic myeloid leukaemia Aged Original Paper Hematology business.industry Cancer Imatinib General Medicine Middle Aged Protein-Tyrosine Kinases medicine.disease Nilotinib Regimen 030104 developmental biology Oncology Adherence 030220 oncology & carcinogenesis Physical therapy Female business Tyrosine kinase medicine.drug |
| Zdroj: | Medical Oncology (Northwood, London, England) |
| ISSN: | 1559-131X 1357-0560 |
| Popis: | Failure to comply with treatment recommendations is very common in patients, but still poorly recognised by doctors. The current practice of using oral therapy on a large scale has been increasingly adopted for cancer patients. Chronic myeloid leukaemia (CML) is just such an example, where the introduction of taking new oral medications, the tyrosine kinase BCR-ABL inhibitors (TKI), has now revolutionised the treatment. The aim of our study was to assess treatment adherence in a group of Polish CML patients (a survey was conducted on 140 patient aged ≥18 years) treated with oral TKI (imatinib, dasatinib and nilotinib) taking into account the following variables: gender, age, education, place of residence, family circumstances and duration of therapy. In addition, we evaluated whether there is a relationship between how patients perceive their level of adherence to treatment recommendations with how subjectively the required dosage regimen was followed. Half the patients admitted to skipping at least one drug dose during the entire course of treatment and 39% did so within their last treatment month. Patients were also found to overestimate their own adherence assessment; around 60% of those missing at least 1 drug dose within the last treatment month believed they ‘always’ followed recommendations. The study demonstrated that adherence deteriorates over time. Furthermore, patients aged >65 years and patients suffering at least one comorbid disease had better adherence (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink